Advising women at high risk of breast cancer

ONCOLOGY

Volumn 18, Issue 1, 2004, Pages 28-32

  Wood, William C ^a  

^a EMORY UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BREAST TUMOR; CHEMOPROPHYLAXIS; COUNSELING; DECISION MAKING; FEMALE; GENETICS; HUMAN; MAMMOGRAPHY; MASTECTOMY; RISK FACTOR; TUMOR SUPPRESSOR GENE;

BREAST NEOPLASMS; CHEMOPREVENTION; COUNSELING; DECISION MAKING; FEMALE; GENES, BRCA1; GENES, BRCA2; HUMANS; MAMMOGRAPHY; MASTECTOMY; RISK FACTORS;

EID: 2142650069     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Srivastava A, McKinnon W, Wood ME: Risk of breast and ovarian cancer in women with strong family histories. Oncology 15:905-907, 911-913, 2001.
2. Available at http://www.myriadtests.com/provider/mutprev.htm. Accessed November 14, 2003.
3. Available at http://astor.som.jhmi.edu/brcapro/. Accessed November 14, 2003.
4. Kuhl CK, Schrading S, Leutner CC, et al: Surveillance of "high risk" women with proved or suspected familial (hereditary) breast cancer: First mid-term results of a multi-modality clinical screening trial (abstract 4). Proc Am Soc Clin Oncol 22:2, 2003.
5. Kriege M, Breckelmans CTM, Boetes C, et al: MRI screening or breast cancer in women with high familial and genetic risk: First results of the Dutch MRI screening study (MRISC) (abstract 5). Proc Am Soc Clin Oncol 22:2, 2003.
6. Meijers-Heijboer H, van Geel B, van Putten WLJ, et al: Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 345:159-164, 2001.
7. Fisher B, Costantino JP, Wickerham DL, et al: Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90:1371-1388, 1998.
8. Narod SA, Brunet JS, Ghadirian P, et al: Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: A case-control study. Hereditary Breast Cancer Clinical Study Group. Lancet 356:1876-1881, 2000.
9. Kauf ND, Satagopan JM, Robson ME, et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 346:1609-1615, 2002.
10. Rebbeck TR: Prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 18:100S-103S, 2002.
11. Weber BL: Risk management in BRCA1 and BRCA2 mutation carriers: Lessons learned, challenges posed. J Clin Oncol 20:1164-1166, 2002.
12. Eisen A, Rebbeck TR, Wood WC, et al: Prophylactic surgery in women with hereditary predisposition for breast and ovarian cancer. J Clin Oncol 18:1980-1995, 2000.
13. Klamer TW, Donegan WL, Max MH: Breast tumor incidence in rats after partial mammary resection. Arch Surg 118:933-935, 1983.
14. Wong JH, Jackson CF, Swanson JS, et al: Analysis of the risk reduction of prophylactic partial mastectomy in Sprague-Dawley rats with 7, 12-dimethylbenzanthracene-induced breast cancer. Surgery 99:67-71, 1986.
15. Nelson H, Miller SH, Buck D, et al: Effectiveness of prophylactic mastectomy in the prevention of breast tumors in C3H mice. Plast Reconstr Surg 83:662-669, 1989.
16. Baasch M, Nielsen SF, Engholm G, et al: Breast cancer incidence subsequent to surgical reduction of the female breast. Br J Cancer 73:961-963, 1996.
17. Hartmann LC, Schaid DJ, Woods JE, et al: Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med 340:77-84, 1999.
18. Schrag D, Kuntz KM, Garber JE, et al: Decision analysis: Effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations. N Engl J Med 336:1465-1471, 1997.
19. Pennisi VR, Capozzi A: Subcutaneous mastectomy data: A final statistical analysis of 1500 patients. Aest Plas Surg 13:15-21, 1989.
20. Carlson GW, Styblo TM, Moore B, et al: Skin sparing mastectomy. Oncologic and reconstruction considerations. Ann Surg 225:570-575, 1997.